PVCT Provectus Biopharmaceuticals
Todays post on Twitter, by Vorlon
Before Vorlon's post, I noticed that the verbiage changed a little bit with Dom's post today. The "Stockholder's Letter" has the 2023 goals listed as "The company plans to" and then they go on to list pursue regulatory pathway for ITM, P2/3 combo and read out new data. Dom listed them as "Focus (1)" etc. Now, this could simply be conservation of characters for tweeting purposes, but it could also be read that the number one focus of the company is regulatory approval for ITM. It could also be the chronological order in which they see these goals being accomplished. Not sure, but "Focus (1): We plan to pursue a regulatory pathway for rare disease in-transit melanoma" sounds like that the #1 goal and top priority of the company.
If this is the case, news coming from the company will happen without warning, especially since they haven't announced anything formally about applications. There's no way to calculate accurately when we're within an announcement window. I'm hoping for another reverse split vote which, for me, would give us a hint that something is imminent. Then again, they could always wait until the AM for something like that.
Vorlon told me that he's now reached 1 million shares of PVCT. People can say what they want, but he believes in this company.
"Focus (1): We plan to pursue a regulatory pathway for rare disease in-transit melanoma (a distinct sub-population of Stage III cutaneous melanoma) with monotherapy, intratumoral, small molecule, cancer immunotherapy PV-10®."
This will be TGA approval in Australia in my opinion.
"Focus (2): We plan to design, prepare, and potentially commence a Phase 2/3 RCT of PV-10 + SOC checkpoint vs SOC checkpoint for 1st-line Stage III melanoma"
This will be pursuing a FDA pathway to approval in my opinion.
"$PVCT’s preparation of follow-on work for hepatic #uvealmelanoma (https://twitter.com/hashtag/uvealmelanoma?src=hashtag_click) mets is ongoing; would be under NCT00986661 EC3: PV-10 + checkpoint(s). Our data analysis and assessment were not complete prior to the 2023 sto
ckholder letter, and not ready to communicate yet. THREAD END"
The Uveal indication moving to a P2 is not ready yet due to ongoing P1 Uveal data gathering OS data in my opinion. This will include both monotherapy PV-10 and combo PV-10/Keytruda data sets.
So....Wow!.....shareholders complained of mgt in the past not discussing things and now mgt going all out basically writing a PhD thesis of what they did and why on Twitter.
|return to message board, top of board|